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ABSTRACT
Background: Patient-reported outcome (PRO) instruments are used to
evaluate the effect of medical products on how patients feel or function.
This article presents the results of an ISPOR task force convened to
address good clinical research practices for the use of existing or modiﬁed
PRO instruments to support medical product labeling claims. The focus of
the article is on content validity, with speciﬁc reference to existing or
modiﬁed PRO instruments, because of the importance of content validity
in selecting or modifying an existing PRO instrument and the lack of
consensus in the research community regarding best practices for estab-
lishing and documenting this measurement property.
Methods: Topics addressed in the article include: deﬁnition and general
description of content validity; PRO concept identiﬁcation as the impor-
tant ﬁrst step in establishing content validity; instrument identiﬁcation and
the initial review process; key issues in qualitative methodology; and
potential threats to content validity, with three case examples used to
illustrate types of threats and how they might be resolved. A table of steps
used to identify and evaluate an existing PRO instrument is provided, and
ﬁgures are used to illustrate the meaning of content validity in relationship
to instrument development and evaluation.
Results & Recommendations: Four important threats to content validity
are identiﬁed: unclear conceptual match between the PRO instrument
and the intended claim, lack of direct patient input into PRO item
content from the target population in which the claim is desired, no
evidence that the most relevant and important item content is contained
in the instrument, and lack of documentation to support modiﬁcations to
the PRO instrument. In some cases, careful review of the threats to
content validity in a speciﬁc application may be reduced through addi-
tional well documented qualitative studies that speciﬁcally address the
issue of concern.
Conclusion: Published evidence of the content validity of a PRO instru-
ment for an intended application is often limited. Such evidence is,
however, important to evaluating the adequacy of a PRO instrument for
the intended application. This article provides an overview of key issues
involved in assessing and documenting content validity as it relates to
using existing instruments in the drug approval process.
Keywords: content validity, instruments, outcomes, patient-reported out-
comes, validity.
Background to theTask Force
In January 2007, the ISPOR Health Science Policy Council rec-
ommended to the ISPOR Board of Directors that an ISPOR
Patient-Reported Outcomes (PRO) Task Force on Use of Existing
Instruments and their Modiﬁcation be established. The Board of
Directors approved this PROTask Force inMarch 2007. The PRO
Task Force chair and members were chosen based on their expe-
rience as scientiﬁc leaders in the ﬁeld, as well as developers and
users of PRO instruments. A range of perspectives on PRO
instruments was provided by the diversity of their work experi-
ence: research organizations, government, academia, and
industry.
The PRO Task Force met every 6 weeks to develop the report
outline and discuss issues that arose in the manuscript’s devel-
opment. The manuscript outline was presented for comment at
ISPOR 12th Annual International Meeting, Arlington, VA, USA
in 2007. The ﬁrst draft report was presented for comment at the
13th Annual International Meeting, Toronto, Canada in 2008.
In March 2009, the second draft report was submitted for
review and comments to the 360 members of the ISPOR PRO
Special Interest Group. Comments were discussed and incorpo-
rated. A revised draft report was presented for ﬁnal comment at
the ISPOR 14th Annual International Meeting, Orlando, FL,
USA in May 2009. The task force then addressed and incorpo-
rated comments elicited during this ﬁnal review process as appro-
priate. All written comments on the PRO Existing Instruments
and Their Modiﬁcation Task Force Report are available on
the ISPOR Web site at: http://www.ispor.org/TaskForces/
PROInstrumentsUse.asp.
Introduction
During early deliberations, the task force discussed the impor-
tance of content validity in selecting or developing a modiﬁed
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version of an existing PRO instrument and the lack of consensus
in the research community regarding best practices for establish-
ing and documenting this important measurement property. The
task force decided to focus their review and discussion on content
validity in PRO evaluation with speciﬁc reference to existing or
modiﬁed instruments. It should be noted that this article is meant
to represent current best practices in assessing the content validity
of existing PRO instruments for purposes of making a regulatory
claim rather than a repetition of the Food and Drug Administra-
tion (FDA) Draft PRO Guidance [1]. We feel that the recommen-
dations in this article are consistent with the guidance; however,
terminology and interpretation may vary slightly. A working
knowledge of instrument development and qualitative methods is
assumed; those readers who desire to know more about this topic
are encouraged to read one of themany basic textbooks, including
those referenced throughout the document. The article begins
with a deﬁnition and general description of content validity. This
is followed by a discussion of PRO concept identiﬁcation as the
important ﬁrst step in establishing content validity in the context
of a regulated claim (section III). A description of identiﬁcation of
an instrument and the initial review process, summarized in
Table 1 (section IV), is followed by a discussion of key issues in
qualitative methodology, the foundation of content validity
(section V). The article concludes with a discussion of potential
threats to content validity (section VI), with three case examples
used to illustrate types of threats and how they might be resolved,
as presented in Tables 2 and 3. References of existing work in each
of the areas discussed are provided throughout the article to guide
the reader interested in further information.Whereas an overview
of key issues in qualitative research methodology as it relates to
either selecting or developing a modiﬁed version of an existing
instrument is presented, it is not the intent of this article to provide
an in-depth review of these methods which is available in more
detail elsewhere.
Content Validity: Basic Principles
Deﬁnition: The goal of measurement is to quantify a concept.
The Standards for Educational and Psychological Testing, a key
reference describing development and evaluation of instruments
used to evaluate an individual’s behavior, deﬁnes validity as an
overall assessment of the degree to which evidence and theory
support the interpretation of scores entailed by proposed uses of
the instrument [1]. (The Standards for Educational and Psycho-
logical Testing uses the term “tests” rather than “instruments.”
The term “test” may be confusing when used in the context of
PRO research; therefore, the term PRO “instruments” is used in
this document.) One type of validity is based on content. Evi-
dence of content validity is obtained from an analysis of the
relationship between an instrument’s content and the construct it
intends to measure. The Standards for Educational and Psycho-
logical Testing uses the term “construct” as “the concept or
characteristic that a test is designed to measure.” The term
“concept” will be used in this article to be consistent with the
Table 1 Steps in identifying and evaluating an existing PRO measure
Step
 1. Name and deﬁne the concept.
 2. Draft the claim, target population, target product proﬁle, and end point model.
 3. Identify candidate measures.
 4. Identify or formulate a conceptual framework for the instrument(s).
 5. Assemble and evaluate information on development methods.
 a. Elicitation focus groups and interviews; sample size and characteristics relative to intended use; analytical approach; results, including evidence of
saturation
 b. Cognitive interviews; sample size and characteristics relative to intended use; methods (mode of administration); results
 c. Transcripts—for independent review and stratiﬁed analyses; evidence of saturation
 6. Conduct any needed qualitative research.
 a. Prepare documents for decision-making and regulatory submission—including protocol and study report, saturation tables, transcripts.
 b. Map qualitative data to existing instrument items.
 7. Assess adequacy of content validity for purpose.
 a. Identiﬁcation of any concepts, domains, or items relevant to patients in the target population not included in the existing instrument
 b. Assess the relevance and importance of this content
 8. Determine the need for modiﬁcations or new instrument development.
 a. Evaluate cost beneﬁt in terms of need, timelines, and resource allocation.
 b. Discuss alternatives—change the claim/concept; alter PRO positioning.
PRO, patient-reported outcome.
Table 2 Framework (model) for evaluating content validity of an existing instrument within the context of a speciﬁc claim
Element*
Acceptable level
of agreement†
Steps to remediate
(examples)
Documentation of evidence
(resources and examples)
1. Conceptual match‡
2. Input from the target population§
3. Item content, including saturation¶
4. Modiﬁcation, e.g., mode of administration, translation**
*The greater the absence of evidence to substantiate content validity, the more comprehensive the evaluation and the greater the degree of remediation required. Deﬁnitions of the elements
follow:
†Level of evidence refers to the basis on which the elements are evaluated.The following four levels of evidence are proposed: completely met, mostly met, partially met, not met.
‡Conceptual match:The concepts, as deﬁned by the developer and represented by the items in the instrument, match the intended claim.
§Input from the target population: Patient concerns were obtained using appropriate qualitative methods.
¶Item content: Each concept in an item reﬂects patient concerns across the range of patients appropriate for the intended claim.
**Modiﬁcation:Any change in the instrument from the original version needs to be identiﬁed and evaluated for its impact on content validity in terms of the above elements, in addition to the
psychometric performance of the modiﬁed version relative to the original form.
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FDA draft PRO guidance. Content refers to the themes or sub-
jects addressed in the instrument; the wording and format of
items, tasks, or questions on an instrument; as well as the guide-
lines for procedures for administration and scoring. In the
context of content validity, the appropriateness of the content is
related to the speciﬁc inferences to be made from the instrument
scores. An evaluation of content validity is therefore essential in
the selection of instruments to evaluate PROs to be used in
making labeling claims.
The classic text, Psychometric Theory, by Nunnally and
Bernstein [2], notes that there are two major standards for ensur-
ing content validity. One standard is the representative nature of
the collection of items comprising the instrument. Because
“random sampling” is impractical, the method used to identify
and select the items to represent the concept must be explicit. The
second, related standard is based on the methods used in instru-
ment construction, i.e., the rigor with which the instrument is
constructed or formulated, including item and response option
wording, scaling method (e.g., dichotomous, Likert, visual
analog), and organization [1]. The appropriateness of a given
content domain is related to the speciﬁc inferences to be made
from the instrument scores [1].
PRO instruments are designed to capture data related to the
health experiences of individuals, speciﬁcally the way patients feel
or function in relationship to their condition or disease and/or
their treatment. Figure 1 depicts the relationship between disease
attributes, including observed signs and laboratory values, and
patient-reported manifestations of the condition, e.g., symptoms,
and patient experiences, including their descriptions of the disease
and human experiences unrelated to the disease. For any disease,
there are a host of characteristics, including observed signs, labo-
ratory values, and patient-reported manifestations of the disease.
Patients with the disease have a wide range of experiences, includ-
ing those directly related to the disease itself, and other experi-
ences that may be important to the patient’s life experience, but
are not characteristic of the speciﬁc disease of interest. For PRO
instruments, content validity begins with the intersection between
disease characteristics and patient experience, as shown in
Figure 1, and is evaluated in terms of the adequacywithwhich this
intersection “universe” of content is sampled in a given instrument
to accurately capture patient-reported manifestations of the
disease. Although the focus of this article is on PRO instruments
used to support evidence of treatment efﬁcacy, the adequacy of
content validity for instruments to assess adverse treatment
impact would follow the same principles.
In practice, content validity is determined by the relationship
between the intended measurement concept and the methods
used: 1) to develop and select items; 2) to evaluate the content;
and 3) to formulate the instrument. A detailed description of
these methods and their results provides evidence that the pro-
Table 3 Case examples: threats to validity
Scenario A: use of an existing PRO instrument in a new patient population
A PRO measure designed to assess dyspnea is used routinely by pulmonologists in their clinical practice for evaluation and management of patients who have
compromised lung capacity because of various etiologies.This standardized measure was developed and validated in a COPD patient sample.
Question: Does the development and use of this standardized measure in clinical practice support its use in a clinical trial that is being designed to assess
experiences of shortness of breath in persons with asthma, with the ultimate goal of obtaining a label claim for dyspnea?
Issues/threats to content validity:
1. Is the concept of dyspnea, as expressed in the existing instrument, appropriate for persons with asthma?
2. Was the instrument developed based on patient input (e.g., focus groups)?
3. What are the implications of using an instrument developed for managing patient care in a clinical trial?
Approaches to remediation
1. Conduct qualitative analyses to gain understanding of how asthma patients conceptualize dyspnea.
2. Do an extensive literature to determine whether or not patient input has been included either in the instrument’s development or subsequent application.
3. Compare and contrast clinical trial inclusion and exclusion criteria with characteristics of patients in a typical pulmonology practice.
Scenario B: short form of an existing PRO instrument
A multi-item, multiscale PRO measure has been reduced to a shorter, clinically efﬁcient assessment form using accepted item response theory (IRT)
psychometric procedures, including cross-validation in the relevant patient samples, and has been shown to have nearly identical psychometric properties,
including factor structure, to the original long form of the instrument.
Question: Does such a shortened measure pose a threat to content validity for a regulated claim when used in the same patient population in which it was
originally developed?
Issue/threat to content validity:
Did the process of generating the short form eliminate items that then, in turn, change at least one domain that measures a concept that may be essential to
the speciﬁc language of the intended claim?
Approach to remediation
1. Conduct patient interviews or focus groups consisting of representative patients to determine the importance that patients placed on the omitted items
relative to those retained in the shorter version.
Scenario C: focus group appraisal of PRO measure identiﬁes same concepts with different item wording
The sponsor has selected an existing instrument that reportedly has the claim-relevant concept(s), and has been developed for the same population as the
intended study group and decides to verify content validity in a small number of patient focus groups. From these groups, the sponsor learns that the item
content is conﬁrmed as relevant and that the instrument captures the range of experience of the construct being assessed.There does seem to be some
differences, however, in the use by some patients to describe their experience.
Question:Are the different words used by a few of the focus group patients sufﬁciently synonymous in terms of a conceptual match to conﬁrm the content
validity of the original measure?
Issues/threats to content validity:
1. Do the different words used to describe the patient experience truly represent a different aspect of the concept, or is it essentially the same concept
being described with different words?
2. What importance is placed on the number of focus group patients who use different wording (i.e., if one patient, is it cause for concern)? What about two
patients, etc.?
3. Are the differences in wording in the instrument compared to that used by the focus group patients sufﬁcient to require adjustment in the original
measure?
Approaches to remediation
1. Conduct cognitive interviews to assure patient understanding consistent with concept. If the concept is consistent, no additional remediation is required.
2. If the interviews uncover patient misunderstanding, modiﬁcation in the instrument would be required.
COPD, chronic obstructive pulmonary disease; PRO, patient-reported outcome.
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posed use and interpretation of scores from the instrument rep-
resent the intended concept and therefore possess content validity
[1–5]. Documentation of content validity describes the following
three processes: identifying and deﬁning the concept of interest,
identifying the patient experience related to the targeted concept,
and using appropriate methodology to develop the instrument to
capture and quantify the concept.
Concept Identiﬁcation within the
Labeling Context
Selecting or developing a modiﬁed version of an existing PRO
instrument for evaluating treatment efﬁcacy begins with the iden-
tiﬁcation of the concept to be measured and its positioning in
relationship to other trial end points to be used in the develop-
ment program, as described in the United States FDA PRO Draft
Guidance [6]. Outcomes essential for testing product efﬁcacy and
informing appropriate use in clinical practice are considered
highest priority and serve as primary end points in clinical trials.
Outcomes considered important for providing additional under-
standing of treatment beneﬁt or for communicating product
attributes of value to the patient are also identiﬁed early in the
development program and can serve as key secondary end points.
Exploratory end points are useful for product development plan-
ning, including gathering data to inform future trial design deci-
sions, but are not used to support labeling or promotional claims.
PRO instruments can serve as primary, secondary, or exploratory
end points.
Targeting the desired claim using the target product proﬁle
(TPP) approach can be useful when selecting and positioning the
PRO, and linking it to the desired claim [7,8]. An end point model
that describes each study end point, including PRO end points and
their relationship to other end points, may be developed consistent
with the goals identiﬁed in the TPP. An end point model should
clearly delineate the relative importance of each end point in terms
of labeling priorities to inform the subsequent drafting of study
objectives, study protocol, and statistical analysis plan. Each
concept to be measured is included, as well as how each concept
will correspond to the ultimate labeling goals (i.e., the claims).
Selecting and deﬁning the concept, specifying the intended
claim, identifying the target population, and drafting the TPP are
the initial steps in assuring and documenting content validity.
Existing instruments are identiﬁed and reviewed with this infor-
mation in mind.
Instrument Identiﬁcation and Initial
Review Process
Existing PRO instruments can be identiﬁed through literature
searches, Web searches, and dedicated instrument databases. A
review of candidate instruments includes a close examination of
the items (stem and response options), recall period, mode of
administration and instructions in relationship to the targeted
concept in keeping with good scientiﬁc practice [9], and the Draft
PRO Guidance [6].
If a conceptual framework of the instrument is available, it is
examined for consistency with the concept. A conceptual frame-
work is a detailed description or diagram of the relationship
among the concepts, domains, and items comprising the instru-
ment [10,11]. If such a framework does not exist, one should be
developed, showing how the items, subscales, and total scales are
related to one another and to the underlying concept and claim.
The names used to describe the concept and subscales should be
critically evaluated in light of the content and structure of the
items and the targeted PRO claim. Adjustments in the name or
concept referenced in the PRO instrument may be desirable to
more accurately reﬂect the content and link to the claim. These
adjustments, however, should be made after consulting with the
instrument developer, keeping in mind that any name changes
can have an adverse effect on subsequent interpretation and
attempts to replicate ﬁndings. Strong and clear links between
item content, subscale names, concept names, study objectives,
and target claims are desirable and enable ease of understanding,
interpretation, and communication.
A complete understanding of the methods used to develop a
PRO instrument is essential to evaluate the suitability of an
existing PRO instrument for any purpose. These methods are
generally available in published literature and documentation;
however, some may need to be obtained directly from the devel-
oper. An instrument may be best evaluated for potential use to
support claims if: 1) patient-derived qualitative data forming the
basis of the instrument are available; 2) a careful critique shows
Patient Experience
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Observed
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Figure 1 Content validity: the intersection of
disease characteristics and patient experience.
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the data generation methodology to be sound, and a sample
similar to the development program’s target population was
used; and 3) the results of this qualitative work are comprehen-
sive and relevant. Documentation of methods and results should
demonstrate that the instrument is adequate for decision-making,
and appropriate for regulatory submission as part of a PRO
evidence dossier [12].
It is not uncommon for existing instruments to have little to
no published or available information on their development
history, to have little to no patient input in the development
process, or to have minimal qualitative data from the patient
population speciﬁcally enrolled in the trial. In these cases, there is
little empirical evidence for the sponsor or regulatory reviewer to
make an informed decision regarding the content validity of a
PRO instrument, and suitability for the drug development
program. If clinical and research experts conclude that the items
in the PRO instrument may be an adequate representation of the
concept in the intended claim and that there is quantitative
evidence of reliability and validity, then qualitative research
methods can be used to evaluate and substantiate the instru-
ment’s suitability as a trial outcome for labeling claim intent. If it
is decided that changes to an instrument may be beneﬁcial to the
content validity for a particular purpose, it is recommended that
the researcher discuss such changes with the developer as a
professional courtesy, to gather new information as a potential
colleague in the effort, and to avoid violations associated with
copyright law. Because qualitative methods are essential to select-
ing and documenting the content validity of an existing instru-
ment and to performing content valid modiﬁcations if necessary,
the following section provides an overview of key aspects of the
methods particularly relevant to evaluating existing PRO instru-
ments to support regulated claims.
Qualitative Methods: The Foundation of
Content Validity
“Qualitative research methods involve the systematic collection,
organization and interpretation of textual materials from talk or
observation. It is used in the exploration of meanings of social
phenomena as experienced by individuals themselves, in their
natural context” [13]. These empirical methods, speciﬁcally
focus groups and 1:1 interviews, are used to elicit information
from patients to inform instrument development. That is, these
methods are used to obtain descriptive words and phrases, as
shown in Figure 1. Cognitive debrieﬁng interviews, generally
conducted 1:1, are used to evaluate patient understanding of an
instrument, as a draft item pool or as an existing measure being
evaluated for possible use. Items are developed and evaluated
with the target patient population in mind with wording
designed to maximize ease of reading, translatability, and content
coverage, with the ﬁnal instrument reﬂecting all of these consid-
erations. As shown in Figure 2, a PRO instrument is based on the
concepts, words, and phrases generated during elicitation focus
groups and interviews, with adjustments made based on inter-
pretation and meaning provided during cognitive interviews with
a new set of patients. Although patients are experts in their
personal experience with a disease, they are not experts in the
disease pathophysiology or instrument design techniques. Instru-
ment developers play a key role in the development of consensus
wording of items and response options, the selection of recall
period, and the instructions to respondents, based on their
knowledge of the content area and instrument development
techniques.
Sample Selection
For product labeling in the context of a regulated claim, the FDA
Draft PRO Guidance [6] indicates that PRO instruments assess-
ing treatment beneﬁt should show evidence of content validity
using methods that include the elicitation of input from the
patient population for which the claim is intended, and results
that demonstrate the relevance and importance of item content to
this group. Because these instruments are designed to capture
patient experiences, the Draft PRO Guidance suggests this input
be elicited directly from the patients targeted for the clinical
trials. Clinicians or other experts or literature may be useful in
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Figure 2 Content validity: content consensus
through qualitative research.
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preparing interview guides and in deﬁning enrollment criteria in
the qualitative studies, but without patient input, PRO instru-
ment development is incomplete.
Patients should represent variations in severity of the target
condition, as well as in population characteristics such as age,
sex, ethnicity, and language groups in accordance with the antici-
pated characteristics of the patients to be enrolled in the clinical
trials. For example, the content of an existing instrument may
initially have been generated on a broad population of adults
ranging from age 18 to 65 years. Subsequent use of the instru-
ment outside of this age range, e.g., adolescents or older adults,
would require additional qualitative research for eliciting or con-
ﬁrming age-relevant content, testing modiﬁcations of the existing
item content, and determining adequate comprehension of the
instrument items and response format.
Data Collection Methods
Data from 1:1 interviews and/or focus groups with patients form
the basis of PRO instrument content. When evaluating candidate
instruments, users should examine the data collection methods
used to generate the instrument to understand the content valid-
ity of the instrument. Gathering qualitative data through 1:1
interviews or focus groups is both a rigorous scientiﬁc method
requiring a well-deﬁned protocol, and an art requiring trained
and experienced interviewers or focus group moderators. Inter-
views are audio recorded for later transcription and analyses. To
assure representation from all group participants and to assist in
data analyses, focus group interviewers/moderators are trained
to encourage rapport and elicit comments from all participants.
Focus groups can be videotaped and/or audio recorded. An assis-
tant moderator can take notes with participant initials, and key
words or quotations to facilitate data transcription and analyses.
This individual can also map the discussion, marking the fre-
quency with which various participants contribute comments to
the discussion, and alerting the moderator for the need to query
certain participants who have been less active in the discussion.
One-on-one interviews require a skilled interviewer and are
particularly effective for sensitive topics unsuited to a group
discussion, e.g., urinary incontinence, or for patient populations
unable to participate or uncomfortable in a group setting, e.g.,
men with erectile dysfunction. One-on-one interviews are also
used for cognitive interviews in which patients review an existing
instrument or item pool, and can provide the developer with both
insight into the extent to which their interpretations match the
intent of the items and with any critical content that has been
omitted from the instrument.
Cognitive debrieﬁng interviews with patients from the target
population are used to evaluate patient understanding of the
items relative to the concept of interest. Also known as comple-
ment elicitation focus groups or interviews, cognitive interviews
provide additional evidence of content validity. Cognitive inter-
views also provide an opportunity to query patients about the
comprehensiveness of the instrument content relative to their
experiences with the concept of interest, serving as a “pilot test,”
to make certain the instrument selected is, in fact, interpreted
correctly, no additional instructions or special training is
required, and that all of the appropriate concepts are covered.
Speciﬁcally, at the end of the interview, patients may be asked if
there were any aspects of the concept, e.g., experiences, symp-
toms, or sensations that were not addressed in the instrument,
and if so, how important these are to the concept. If missing
themes emerge across multiple interviews, and these themes are
clearly related to the underlying concept, it is likely the instru-
ment is missing important content and should be modiﬁed before
use in a development program. This ﬁnding is referred to as
“construct underrepresentation” [1].
Qualitative data from elicitation or evaluative methods not
only provide information on the content validity of an existing
measure, but also offer insight into concept names used to rep-
resent scales or subscales. As discussed previously, an assessment
of the formulation of the conceptual framework of an instrument
may suggest that scale or subscale names created by developers
are unclear or inaccurate, particularly for regulated claims.
Qualitative data can inform the evaluation of instrument naming
conventions, and suggest alternatives more suited to the concept
and proposed claim. Although it is usually inappropriate to
rename existing instruments and domains, an accurate descrip-
tion of the content may facilitate communication between
researcher and reviewer.
Data Analysis
Analyses of qualitative data use a carefully constructed method-
ology that includes independent coding with inter-rater analyses
and reconciliation. When reviewing instrument development
methods, attention should be paid to how the data were ana-
lyzed. Coding transcripts by participant, using initials or other
coding system to protect anonymity, allows the researchers and
reviewers to evaluate the representativeness of content across
participants, and provides assurance of saturation (discussed in
greater detail below). Coding by a speciﬁc patient characteristic,
such as gender or disease severity, permits stratiﬁed analyses with
an assessment of the consistency in experiences, and the words
and phrases to describe these experiences by patient subgroups.
Reference to this type of analysis can reassure sponsors and
regulators that the instrument development methods were rigor-
ous and that the instrument captures the content most relevant
for the concept across the full range of the target population.
Analyses of focus group and interview data to evaluate and
document the content validity of an existing measure are similar
to those used in instrument development, identifying themes that
emerge from the data in relationship to the concept of interest.
These themes are used as analytical codes that are then mapped
to the existing instrument content, with words and phrases com-
pared with the wording used in the instrument. Figure 3 shows
three examples of the relationship between the content of an
existing measure relative to the universe of content derived
through qualitative research methods. Example A shows a strong
match between the content in the instrument and the information
provided by patients. Note that the instrument content is not all
inclusive, but represents the vast majority of the potential item
content. Example B shows a poor match, with the content cap-
turing less than 30% of the possible concept content. Example C
shows a mismatch, with some of the instruments covering the
content of interest, and coverage of content external to the
concept of interest. It is unlikely that the instruments in examples
B and C would be suitable for use as a primary or key secondary
end point in registration trials because of the inadequate cover-
age of item content in the instrument with relevant information
provided by patients. In such cases, a decision must be made
either to adapt the existing instrument or to develop a new one,
or to re-evaluate the intended claim and relevant PRO concept to
support it.
Saturation
Qualitative data should be gathered to the point of saturation to
ensure that the items in an instrument appropriately represent the
relevant “universe of content” for the concept when conducting
focus groups or 1:1 interviews. In instrument development, satu-
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ration refers to the point in the data collection process when no
new concept-relevant information is being elicited from indi-
vidual interviews or focus groups, or no new information is
elicited and deemed missing during cognitive interviewing. There
is no ﬁxed rule on either the sample size or the number of
iterations needed to reach saturation. During the development
process, evidence is based on empirical observation, where no
new concepts or codes emerge after the nth interview or focus
group [10,14]. Saturation can be evaluated and documented
through a saturation table structured to show the elicitation of
information by successive focus group or interview (individual or
by set), organized by concept code. For practical purposes of
budgeting projects, it is not uncommon to set a sample size of
20–30 interviews, even though saturation may occur earlier in
the interview process. Saturation is then documented for where it
occurs in the process, often during the interviewing process or
sometimes at the end of all interviews. The risk of waiting to the
end of the project before applying a coding frame and analyzing
qualitative data is that saturation may not be reached and addi-
tional interviews will have to be conducted, or that saturation
was evident at some point before the end of the designated
stopping point, and the additional interviews were unnecessary.
It is not at all uncommon for participants in focus groups and
interviews to stray from the intent of the interview, discussing
issues or concepts important to them as individuals or as
patients, but unrelated to the concept of interest (see Fig. 1,
unrelated descriptions). These data are clearly not part of the
core concept, are inconsistent with the intent of the instrument,
and should be excluded from a description of the concept and
saturation tables. This is a particularly important issue when
analyzing qualitative data to evaluate the content validity of an
existing instrument. For example, data from focus groups elicit-
ing information on patient perception of anginal pain as part of
an evaluation of an anginal pain scale may include comments
from one or more patients describing their knee pain. These
descriptions should be coded as part of the patient’s comorbid
experience, but excluded from the thematic summary and
content item mapping.
Identifying and ResolvingThreats to
Content Validity
The fundamental question in the evaluation of a PRO instrument
in the context of a labeling claim, whether an instrument is new,
existing, adapted, or modiﬁed, is the adequacy of empirical evi-
dence to support content validity for the desired claim. Four
important threats to PRO content validity, in relative order of
importance, are shown in Table 2. This table also provides an
organizing heuristic for evaluating each threat; a discussion of
this approach to resolving these threats follows:
Absent or Unclear Conceptual Match Evident between
the PRO Instrument and the Intended Claim
As discussed earlier in the article, the conceptual match is the
primary task in identifying the PRO instrument’s conceptual
framework, and specifying its linkage to the intended claim. If
there is no clear match, then probably the most effective strategy
is to identify another instrument to measure the claim with
targeted concepts relevant for supporting the claim.
Lack of Direct Patient Input into PRO Item
Content from the Target Population in which the
Claim Is Desired
The patient population in which the PRO instrument was devel-
oped should be compared to the patient population targeted for
enrollment in the clinical trials, to determine whether the instru-
ment is appropriate for that population. This requires sponsors
to carefully consider the inclusion and exclusion criteria of the
clinical trial to identify important patient characteristics that may
indicate a need for additional validation work.
Lack of Evidence Regarding Saturation—No Evidence
that the Most Relevant and Important Item Content Is
Contained in the Instrument
This threat addresses limitations in empirical data to conﬁrm that
the PRO item content associated with each concept captures the
full range of important and relevant patient experiences across a
representative sample of the targeted patient population. Evalu-
ative interviews, focus groups, and cognitive debrieﬁng inter-
views can be used to address this threat.
Modiﬁcation of the Original PRO Instrument
Modiﬁcations to an instrument may include: changes in wording
or content, changes in mode of administration, translation and
cultural adaptation, and application to a different patient popu-
(a)  High/Strong Match (b)  Low/Weak Match
(c)  Mismatch
Universe of content
Instrument content
Legend:
Figure 3 Instrument content versus universe of
content.
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lation [10,15]. Two other ISPOR PRO task forces addressed best
practices in relationship to changes in mode of administration
[16], and translation and cultural adaptation [17]. Snyder et al.
[15] note that modiﬁcation of an existing instrument is an accept-
able approach as long as the following conditions hold: the
existing instrument has been adequately validated for a different
application; items in the adapted instrument are relevant and
appropriate for the target application; the instrument is able to
be logistically utilized in the intended setting; and a new inter-
pretation guideline is developed, as needed. The extent of docu-
mentation required to support existing instrument modiﬁcations
will vary depending on the type of modiﬁcation. If it has been
modiﬁed in the way(s) described by Snyder et al. and is to be used
in the regulatory approval process, Burke et al. [10] recommend
that additional qualitative research be conducted.
Case Studies
To illustrate these considerations in evaluating PRO content
validity, we present three case scenarios (Table 3). For each sce-
nario, we identify the key question raised regarding content
validity, identify the major threats, and offer sample approaches
for remediation. These approaches are intended to be illustrative
and in no way prescriptive.
In scenario A, a PRO measure was developed by clinicians to
assess dyspnea in chronic obstructive pulmonary disease in clini-
cal practice. The question here is whether the instrument could
be used to evaluate treatment efﬁcacy in clinical trials involving a
new patient population, i.e., asthma. In this example, the ﬁrst
threat is that there may be aspects of the concept of “dyspnea”
that are experienced uniquely by asthma patients and are not
addressed in the instrument. A review of the literature and dis-
cussions with the developer may uncover qualitative study
reports in which data from patients with asthma are presented as
part of the instrument development process or by others inter-
ested in using the instrument in asthma. The review might also
uncover independent qualitative studies examining the concept
of dyspnea as experienced by patients with asthma with charac-
teristics similar to those to be enrolled in the trials.
The second threat in this example is the potential that the
instrument was developed without patient input. This is
addressed by reviewing all of the documentation from the devel-
oper(s) for evidence of direct patient input. The material should
provide a detailed description of all of the steps that were taken
to identify instrument content, and to generate speciﬁc items
based on patient data. Instruments developed before 2000 often
lack this information entirely or in the detail needed to support
labeling claims following the FDA Draft PRO Guidance [6].
Remediation for this problem is discussed below.
A third threat involves the change in intended use of the
instrument, from clinical practice to clinical trial. From a content
validity standpoint, the most important element of this threat is
the method used to inform the overall design of the instrument,
including recall period and item content. It is not uncommon for
clinical instruments to be developed based solely on clinician
expertise and experience, with content that addresses the speciﬁc
information needs of the practice setting. For example, if the
instrument was developed using qualitative research methods
with direct input from patients with asthma similar to those to be
enrolled in the clinical trial, and if results of this work are
available, the magnitude of the threat declines. This is not the
case in scenario A.
If documentation provided by the developer or available in
the published literature is inadequate for informed decision-
making, and/or insufﬁcient for regulatory submission, additional
work will be needed. In this scenario, one approach that could be
used is to conduct focus groups and/or cognitive interviews with
asthma patients who meet the inclusion/exclusion criteria for the
product development trials, mapping the results to the instru-
ment. This would enable the user to evaluate concept coverage
and, if adequate, provide data for documenting the relationship
between patient data and instrument content in the target popu-
lation. If the content is found to be inadequate, this process
would provide the sponsor with an opportunity to modify the
instrument, with permission, and perhaps participation, of the
instrument developer, with the potential for increasing the sensi-
tivity of the instrument to detect treatment effects in clinical trials
involving this new target population.
Scenario B illustrates a second example of a potential threat
to content validity. In this example, an existing, multi-item, mul-
tiscale measure has been reduced to a shorter, more efﬁcient
assessment form using psychometric procedures, including cross-
validation in the relevant patient samples, and has been shown to
have nearly identical psychometric properties, including factor
structure, to the original long form of the instrument. Here, the
fact that there is evidence that the original factor structure is
retained suggests that the original concept, or set of concepts, is
still captured by the retained items in the short form. It is pos-
sible, however, that items representing concepts essential to the
intended claim language were deleted in the process of creating
the short form. For example, the physical function domain of a
given instrument consists of multiple items that assess both upper
and lower body function. During the item reduction process, all
of the upper body functions are eliminated. The user must evalu-
ate whether this change threatens the content validity of the
remaining instrument in light of the items eliminated and the
speciﬁc label claim language intended.
It is important to note that content validity involves the
adequate sampling of content from the universe of all possible
content to measure the concept of interest. To understand the
extent to which content validity might be threatened by reducing
certain items, cognitive debrieﬁng interviews in the target popu-
lation could be conducted to determine if item content consid-
ered essential to the concept had been eliminated. If this is the
case, interviews will also determine the extent to which such item
content was considered both relevant to the concept and impor-
tant enough to the patients that the absence of the items may
compromise measurement. Items that are redundant or closely
related to other items provide no unique information and are
unlikely to contribute meaningful information to the assessment
of the concept. Eliminating redundant items is expected to leave
the intended measurement concept intact. In this scenario, quali-
tative evaluation is recommended, even if results of quantitative
assessment of the short form (reliability, validity, responsiveness)
correlate with the long form.
In the last example, scenario C, the sponsor has selected an
existing instrument that was developed to capture the claim-
relevant concept(s) in the same target population as the intended
study group, and appears to be appropriate for use in product
efﬁcacy trials. To be certain, the sponsor elects to verify content
validity of the instrument in a small number of patients using
focus groups. From these groups, the sponsor learns that the
concept(s) is relevant, and the item content reﬂects the full range
of relevant experience described by the patients. However,
patients in the focus groups use different words or phrases than
those used in the instrument. As discussed previously, items and
response options comprising an instrument represent a consensus
of the best wording for content validity. Cognitive debrieﬁng
interviews could be performed to verify that patients understand
the instrument and interpret the items in a manner consistent
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with the intent. If this is not the case, the original instrument may
need modiﬁcation.
Conclusions
Content validity refers to the extent to which an instrument
contains the relevant and important aspects of the concept(s) it
intends to measure. This article discussed the key issues involved
in assessing and documenting the content validity of an existing
instrument, including concept clariﬁcation, instrument identiﬁ-
cation, and initial review, as well as qualitative methods as they
might be used to evaluate the suitability of one or more existing
instruments. Case examples illustrate threats to content validity
and various approaches for remediating these threats. Several
tools were identiﬁed to aid in the evaluation of content validity,
including end point models that describe the correspondence
between concepts, measures, and labeling goals; the conceptual
framework of the PRO instrument to evaluate and communicate
the extent of the match between item content and targeted con-
cepts; and qualitative research methods that form the empirical
basis for evaluating and documenting content validity.
Source of ﬁnancial support: The views expressed herein represent those of
the authors and not those of Johnson & Johnson, the FDA, OLGA, United
BioSource Corporation, University of Washington, or Pﬁzer.
References
1 American Educational Research Association APA, National
Research Council on Measurement in Education. Standards for
Educational and Psychological Testing. Washington, DC: AERA,
1999.
2 Nunnally JC, Bernstein I. Psychometric Theory (2nd ed.). New
York: McGraw-Hill Book Company, 1978.
3 Cook DA, Beckman TJ. Current concepts in validity and reliabil-
ity for psychometric instruments: theory and application. Am J
Med 2006;119:166.e7–16.
4 Frost MH, Reeve BB, Liepa AM, et al. What is sufﬁcient evidence
for the reliability and validity of patient-reported outcome mea-
sures? Value Health 2007;10(Suppl. 2):S94–105.
5 Haynes S, Richard DC, Kubany ES. Content validity in psycho-
logical assessment: a functional approach to concepts and
methods. Psychol Assess 2005;7:238–47.
6 FDA. Food and Drug Administration draft guidance for industry
on patient-reported outcome measures: use in medical product
development to support labeling claims. Federal Register 2006.
7 FDA. Food and Drug Administration draft target product ﬁle—a
strategic development process tool. Federal Register 2007.
8 Delasko J, Cocchetto DM, Burke LB. Target product proﬁle:
beginning drug development with the end in mind. UPDATE
2005;January/February.
9 Turner RR, Quittner AL, Parasuraman BM, et al. Patient-
reported outcomes: instrument development and selection issues.
Value Health 2007;10(Suppl. 2):S86–93.
10 Burke LB, Kennedy DL, Miskala PH, et al. The use of patient-
reported outcome measures in the evaluation of medical products
for regulatory approval. Clin Pharmacol Ther 2008;84:281–3.
11 Patrick DL, Burke LB, Powers JH, et al. Patient-reported out-
comes to support medical product labeling claims: FDA perspec-
tive. Value Health 2007;10(Suppl. 2):S125–37.
12 Revicki DA, Gnanasakthy A, Weinfurt K. Documenting the ratio-
nale and psychometric characteristics of patient reported out-
comes for labeling and promotional claims: the PRO Evidence
Dossier. Qual Life Res 2007;16:717–23.
13 Malterud K. Qualitative research: standards, challenges, and
guidelines. Lancet 2001;358:483–8.
14 Cohen D, Crabtree B. Qualitative Research Guidelines Project.
Available from: http://www.qualres.org/index.html [Accessed
December 23, 2008].
15 Snyder C, Watson ME., Jackson JD, et al. The Mayo/FDA
patient-reported outcome instrument selection: designing a mea-
surement strategy. Value Health 2007;10:S76–85.
16 Coons S, Gwaltney CJ, Hays RD, et al. Recommendations on
evidence needed to support measurement equivalence between
electronic and paper-based patient-reported outcome (PRO) mea-
sures: ISPOR ePRO good research practices task force report.
Value Health 2009;12:419–29.
17 Wild D, Eremenco S, Mear I, et al. Multinational trials—
recommendations on the translations required, approaches to
using the same language in different countries, and the approaches
to support pooling the data: the ISPOR patient reported outcomes
translation & linguistic validation good research practices task
force report. Value Health 2009;12:430–40.
Content Validity of Existing PRO Instruments 1083
